Image source: Shutterstock.com

Highlights

  • EBOS Group is a diversified Australasian marketer, distributor and wholesaler of medical, healthcare and pharmaceutical products
  • In FY23, the company reported 14% YoY increase in its revenue to AUD 12.2 billion
  • Sybos Holdings Pte. Ltd. has the maximum stake in EBO with a shareholding of around 18.84%

EBOS Group Limited (ASX: EBO) is an ASX-listed diversified Australasian marketer, distributor and wholesaler of medical, healthcare and pharmaceutical products. The company is also engaged in the distribution and marketing of known animal care brands. The company operates in 108 locations across Southeast Asia, New Zealand and Australia.

In the financial year 2023 (FY23), the company achieved record results through organic growth and previous year’s acquisition. During FY23, company’s revenue increased by 14% YoY to AUD 12.2 billion, underlying EBITDA surged by 33.3% YoY to AUD 582 million and NPAT grew by 25.1% YoY to AUD 253.4 million.

The record financial performance was driven by diversified growth strategy of the company and the period also saw contributions from the acquisition undertaken in FY22.

Top 10 shareholders of EBO

The top 10 shareholders of EBO have around 34.69% shareholding in the company, while the top four have 27.74% shareholding. The top two shareholders of IEL are Sybos Holdings Pte. Ltd. and Capital Research Global Investors, with a shareholding of ~18.84% and ~3.68%, respectively.

Recent business update

Through an ASX announcement dated 10 January 2024, the company shared an update on its interim FY24 results. Interim financial results for the half year ended 31 December 2023 are expected to be released on 21 February 2024.

On 19 December 2023, the company notified that one of its wholly owned subsidiaries has increased its shareholding in Transmedic Pte Ltd from 51% to 90%. Transmedic is an independent medical device distributor in Southeast Asia.

According to an ASX-filing dated 22 November 2023, underlying revenue of EBO increased by 8.2% YoY during the first four months of FY24 and underlying EBITDA grew by 8.8% YoY.

Outlook

In FY24, the company expects to deliver another year of profitable growth. Multiple new product launches are in company’s pipeline..

The company expects capital expenditure in FY24 to be similar to FY23 levels as it continues to invest in modernising and growing its facilities, especially in the New Zealand healthcare operations. From FY25 onwards, capital expenditure is expected to reduce.

EBO is focused on improving operational infrastructure, expanding distribution network and exploring merger and acquisition opportunities.

Share performance of EBO

EBO shares closed 0.63% up at AUD 33.77 apiece on 24 January 2024. Including today’s gain, EBO’s share price has dropped by 19.04% in the last one year and has increased by 5.60% in the last three months.

The 52-week high of EBO is AUD 45.77, recorded on 17 January 2023, while the 52-week low is AUD 31.28, recorded on 30 October 2023.

 

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 24 January 2024. The reference data in this report has been partly sourced from REFINITIV.